Comparing BioSpecifics Technologies (BSTC) & Tyme Technologies (TYME)

BioSpecifics Technologies (NASDAQ: BSTC) and Tyme Technologies (NASDAQ:TYME) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for BioSpecifics Technologies and Tyme Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSpecifics Technologies 0 0 1 0 3.00
Tyme Technologies 0 0 3 0 3.00

BioSpecifics Technologies currently has a consensus price target of $65.00, indicating a potential upside of 62.50%. Tyme Technologies has a consensus price target of $8.25, indicating a potential upside of 106.77%. Given Tyme Technologies’ higher possible upside, analysts plainly believe Tyme Technologies is more favorable than BioSpecifics Technologies.


This table compares BioSpecifics Technologies and Tyme Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSpecifics Technologies 42.40% 19.11% 16.84%
Tyme Technologies N/A -196.81% -136.25%

Earnings and Valuation

This table compares BioSpecifics Technologies and Tyme Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioSpecifics Technologies $26.25 million 10.96 $11.37 million $1.59 25.16
Tyme Technologies N/A N/A -$15.20 million ($0.17) -23.47

BioSpecifics Technologies has higher revenue and earnings than Tyme Technologies. Tyme Technologies is trading at a lower price-to-earnings ratio than BioSpecifics Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioSpecifics Technologies has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Tyme Technologies has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500.

Institutional and Insider Ownership

55.0% of BioSpecifics Technologies shares are held by institutional investors. Comparatively, 2.5% of Tyme Technologies shares are held by institutional investors. 21.5% of BioSpecifics Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


BioSpecifics Technologies beats Tyme Technologies on 10 of the 12 factors compared between the two stocks.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Tyme Technologies Company Profile

Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with's FREE daily email newsletter.

Leave a Reply